Early Versus Delayed Enteral Feeding to Treat People With Acute Lung Injury or Acute Respiratory Distress Syndrome (The EDEN Study) (EDEN)

Prospective, Randomized, Multi-Center Trial of Initial Trophic Enteral Feeding Followed by Advancement to Full-Calorie Enteral Feeding vs. Early Advancement to Full-Calorie Enteral Feeding in Patients With Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS)

Acute respiratory distress syndrome (ARDS) and acute lung injury (ALI) are medical conditions that occur when there is severe inflammation and increased fluids in both lungs, making it difficult for the lungs to function properly. Hospital treatment for a person with ALI/ARDS often includes the use of a breathing machine, or ventilator, until the person is able to breathe without assistance. Initiating proper nutrition through a feeding tube early in a person's hospital stay may help to improve recovery, but the optimal timing, composition, and amount of feeding treatments remain unknown. This study will evaluate whether early or delayed full-calorie feeding through a feeding tube is more effective in reducing recovery time and increasing survival rates in people with ALI/ARDS.

Study Overview

Detailed Description

ALI/ARDS involves extensive inflammation in the lungs that can lead to rapid respiratory failure. These conditions are most commonly caused by pneumonia, generalized infection, or severe trauma to the lungs, but can also be less commonly caused by smoke or salt water inhalation, drug overdose, or shock.

For some people, ALI/ARDS resolves without treatment, but many severe cases result in hospitalization in the intensive care unit (ICU), where 30% to 40% of cases end in mortality. Current treatments for ALI/ARDS include assisted breathing with a ventilator, supportive care, and management of the underlying causes. Enteral feeding, in which patients receive nutrition through a feeding tube, plays an important role in treatment, too. Some recent studies have shown that enteral feeding initiated soon after a patient begins assisted breathing is associated with a shorter hospital stay and a better chance of survival than delayed enteral feeding. However, other studies have shown the opposite, and studies on optimal feeding volume and composition have shown conflicting results. This study will evaluate the effects of early versus delayed full-calorie enteral feeding on mortality, ventilator-free days, ICU-free days, and organ failure in people with ALI/ARDS.

Upon admission to the ICU, a dietary evaluation will be done on each participant to determine goal, or full-calorie, feeding rates, which will be based on body weight and daily energy consumption. Participants will also undergo baseline assessments and procedures, which will include vital sign measurements, blood draws, a frontal chest radiograph, ventilator settings, and placement of a feeding tube. Participants will be randomly assigned to receive initial enteral feedings that are either minimal (trophic) or full-calorie. All participants will begin enteral feeding within 6 hours of treatment assignment.

Participants assigned to initial minimal enteral feedings will receive feedings at 10 cubic centimeters (cc) per hour, to be continued at this rate for 144 hours, provided that the participant remains on the ventilator. After the 144 hours, the feeding rate will be advanced to full-calorie rates.

Participants assigned to initial full-calorie enteral feedings will receive feedings at 25 cc per hour, and the feeding rate will be increased by 25 cc per hour every 6 hours until the goal rate is reached. During enteral feedings, gastric residual volumes (GRVs) will be checked every 6 to 12 hours to assure acceptable levels. Participants will complete enteral feedings upon hospital discharge, Day 28 of treatment, death, or ability to achieve 48 hours of unassisted breathing.

Blood pressure, heart rate, ventilation settings, and various blood factors will be measured during treatment. Phone-based follow-up assessments will occur at Months 6 and 12 after ICU discharge and will include measurements of health-related quality of life; psychological, neurocognitive, and physical activity outcomes; healthcare utilization; and mortality.

Study Type

Interventional

Enrollment (Actual)

1000

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • Fresno, California, United States
        • University of San Francisco-Fresno Medical Center
      • Sacramento, California, United States
        • University of California, Davis Medical Center
      • San Francisco, California, United States
        • University of California, San Francisco (UCSF)-Moffitt Hospital
    • Colorado
      • Denver, Colorado, United States
        • University of Colorado Health Sciences Center
      • Denver, Colorado, United States
        • Centura St. Anthony Central Hospital
      • Denver, Colorado, United States
        • Denver Health Medical Center
      • Denver, Colorado, United States
        • Rose Medical Center
    • District of Columbia
      • Washington DC, District of Columbia, United States
        • Washington Hospital Center
    • Louisiana
      • Baton Rouge, Louisiana, United States
        • Baton Rouge General Hospital-Blue Bonnet
      • Baton Rouge, Louisiana, United States
        • Baton Rouge General Hospital-Midcity
      • Baton Rouge, Louisiana, United States
        • Earl K. Long Medical Center
      • Baton Rouge, Louisiana, United States
        • Our Lady of the Lake Regional Medical Center
      • New Orleans, Louisiana, United States
        • Ochsner Clinic Foundation
      • New Orleans, Louisiana, United States
        • Medical Center of Louisiana
      • New Orleans, Louisiana, United States
        • Tulane University Health Sciences Center
    • Maryland
      • Baltimore, Maryland, United States
        • Johns Hopkins Bayview Medical Center
      • Baltimore, Maryland, United States
        • Johns Hopkins Hospital
      • Baltimore, Maryland, United States
        • University of Maryland Shock Trauma Center
      • Baltimore, Maryland, United States
        • Union Memorial Hospital
    • Massachusetts
      • Springfield, Massachusetts, United States
        • Baystate Medical Center
    • Minnesota
      • Rochester, Minnesota, United States
        • Rochester Methodist Hospital
      • Rochester, Minnesota, United States
        • St. Mary's Hospital, Mayo Clinic
    • North Carolina
      • Durham, North Carolina, United States
        • Duke University Medical Center
      • Durham, North Carolina, United States
        • Durham Regional Medical Center
      • Greensboro, North Carolina, United States
        • Moses Cone Health System
      • Greensboro, North Carolina, United States
        • Wesley Long Community Hospital
      • Winston Salem, North Carolina, United States
        • Wake Forest University Baptist Medical Center
    • Ohio
      • Cleveland, Ohio, United States
        • University Hospitals of Cleveland
      • Cleveland, Ohio, United States
        • Cleveland Clinic Foundation
      • Cleveland, Ohio, United States
        • MetroHealth Medical Center
    • Tennessee
      • Nashville, Tennessee, United States
        • Vanderbilt University Medical Center
    • Texas
      • Houston, Texas, United States
        • Baylor College of Medicine
    • Utah
      • Murray, Utah, United States
        • Intermountain Medical Center
      • Ogden, Utah, United States
        • McKay-Dee Hospital
      • Provo, Utah, United States
        • Utah Valley Regional Medical Center
      • Salt Lake City, Utah, United States
        • LDS Hospital
    • Virginia
      • Charlottesville, Virginia, United States
        • University of Virginia Medical Center
    • Washington
      • Seattle, Washington, United States
        • University of Washington
      • Seattle, Washington, United States
        • Harborview Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

13 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Must meet the following three criteria within a 24-hour period of study entry: 1) PaO2/FiO2 less than or equal to 300 (if altitude is more than 1000 meters, then PaO2/FiO2 less than or equal to 300 x [barometric pressure/760]), 2) bilateral infiltrates (patchy, diffuse, homogeneous, or asymmetric) consistent with pulmonary edema on frontal chest radiograph, and 3) requirement for positive pressure ventilation via endotracheal tube
  • No clinical evidence of left-sided cardiac failure to account for bilateral pulmonary infiltrates
  • Intention of primary medical team to enterally feed the patient
  • Undergoes enteral feeding within 48 hours of meeting other inclusion criteria

Exclusion Criteria:

  • Neuromuscular disease that impairs ability to breathe without assistance, such as cervical spinal cord injury at level C5 or higher, amyotrophic lateral sclerosis, Guillain-Barré syndrome, or myasthenia gravis
  • Pregnant or breastfeeding
  • Severe chronic respiratory disease (more information about this criterion can be found in the protocol)
  • Burns on greater than 40% total body surface area
  • Cancer or other irreversible disease or condition for which 6-month mortality is estimated to be greater than 50% (more information about this criterion can be found in the protocol)
  • Allogeneic bone marrow transplant in the 5 years before study entry
  • Patient, surrogate, or physician not committed to full support (exception: a patient will not be excluded if he/she would receive all supportive care except for attempts at resuscitation from cardiac arrest)
  • Severe long-term liver disease (Child-Pugh score of 11 to 15)
  • Diffuse alveolar hemorrhage from vasculitis
  • Morbid obesity, defined as 1 kg/cm body weight
  • Unwilling or unable to use the ARDS network 6 mL/kg PBW ventilation protocol
  • Moribund patient not expected to survive 24 hours after study entry
  • No intent to obtain central venous access for monitoring intravascular pressures
  • More than 72 hours since mechanical ventilation initiated
  • Refractory shock (more information about this criterion can be found in the protocol)
  • Unable to obtain enteral access
  • Presence of partial or complete mechanical bowel obstruction
  • Presence of ischemia or infarction
  • Current total parenteral nutrition (TPN) use or intent to use TPN within 7 days of study entry
  • Severe malnutrition with body mass index less than 18.5 or loss of more than 30% total body weight in the 6 months before study entry
  • Laparotomy expected within 7 days of study entry
  • Unable to raise head of bed 30 to 45 degrees
  • Short-bowel syndrome or absence of gastrointestinal tract
  • Presence of high-output (greater than 500 cc/day) enterocutaneous fistula
  • International normalized ratio greater than 5.0, platelet count less than 30,000/mm3, or history of bleeding disorder
  • Intracranial hemorrhage in the 1 month before study entry
  • Allergy to enteral formula
  • Requirement for, or physician insistence on, enteral formula supplemented with omega-3 fatty acids (e.g., Oxepa®, Impact®) or treatment with omega-3 fatty acid, gamma-linolenic acid (GLA), or antioxidant supplementation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 1
Participants will receive initial minimal (trophic) enteral feeding.
Upon admission to the ICU, enteral feeds will be started at 10 cc per hour and continued at this rate for 144 hours. After 144 hours of trophic enteral feeds, the feeding rate will be advanced to full-calorie rates, which will continue for the duration of mechanical ventilation up to Day 28.
Experimental: 2
Participants will receive initial full-calorie enteral feeding.
Upon admission to the ICU, a full-calorie feeding rate will be determined, which will be calculated to deliver 25 to 35 kcal/kg predicted body weight (PBW) each day. Enteral feeds will be initiated at 25 cc per hour. The feeding rate will be increased by 25 cc per hour every 6 hours until goal rate is achieved, which will be administered for the duration of mechanical ventilation up to Day 28.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Number of ventilator-free days (VFD)
Time Frame: Measured at Day 28
Measured at Day 28
Mortality before hospital discharge, with unassisted breathing
Time Frame: Measured at Days 60 and 90
Measured at Days 60 and 90

Secondary Outcome Measures

Outcome Measure
Time Frame
Number of intensive care unit-free days
Time Frame: Measured at Day 28
Measured at Day 28
Number of organ failure-free days (liver, kidney, heart, central nervous system, and hematologic)
Time Frame: Measured at Day 28
Measured at Day 28
Incidence of ventilator-associated pneumonia
Time Frame: Measured at Day 28
Measured at Day 28
Number of days from first meeting criteria for weaning readiness to Day 28
Time Frame: Measured at Day 28
Measured at Day 28
VFDs and mortality in participants with a partial pressure of oxygen in arterial blood (PaO2)/fraction of inspired oxygen (FIO2) less than or equal to 200 or with shock at the time of study entry
Time Frame: Measured at Days 28 and 60, respectively
Measured at Days 28 and 60, respectively
Change in plasma and mini-bronchoalveolar lavage (BAL) levels of interleukin (IL)-6, IL-8, von Willebrand factor (VWF), surfactant protein D (SPD), and total protein concentrations
Time Frame: Measured at Day 3
Measured at Day 3
Health-related quality of life; healthcare utilization; and psychological, neurocognitive, and physical activity outcomes
Time Frame: Measured at Months 6 and 12
Measured at Months 6 and 12
Duration of survival after hospital discharge using the National Death Index
Time Frame: Measured at Months 6 and 12
Measured at Months 6 and 12

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Arthur P. Wheeler, MD, Vanderbilt University Medical Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2007

Primary Completion (Actual)

March 1, 2011

Study Completion (Actual)

May 1, 2011

Study Registration Dates

First Submitted

April 17, 2009

First Submitted That Met QC Criteria

April 17, 2009

First Posted (Estimate)

April 20, 2009

Study Record Updates

Last Update Posted (Estimate)

April 13, 2016

Last Update Submitted That Met QC Criteria

April 12, 2016

Last Verified

February 1, 2012

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Study Data/Documents

  1. Individual Participant Data Set
    Information identifier: ARDSNet-EDEN
    Information comments: NHLBI provides controlled access to IPD through BioLINCC. Access requires registration, evidence of local IRB approval or certification of exemption from IRB review, and completion of a data use agreement.
  2. Study Protocol
  3. Study Forms

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Respiratory Distress Syndrome, Adult

Clinical Trials on Minimal (Trophic) Feeding

3
Subscribe